Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ALL Assembly 2018

Immunological monitoring of patients receiving immunotherapy

Prof Jaques van Dongen - Leiden University, Netherlands

Immunological monitoring of patients receiving immunotherapy ( Prof Jaques van Dongen - Leiden University, Netherlands )

Novel therapies for paediatric B-ALL

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Novel therapies for paediatric B-ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Can we reduce the intensity of frontline therapy?

Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy

Can we reduce the intensity of frontline therapy? ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )

Latest concepts in the diagnosis of genetic ALL subtypes

Dr Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA

Latest concepts in the diagnosis of genetic ALL subtypes ( Dr Charles Mullighan - St Jude Children's Research Hospital, Memphis, USA )

In vitro diagnostic models for ALL: what can we learn on actionable targets?

Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland

In vitro diagnostic models for ALL: what can we learn on actionable targets? ( Dr Beat Bornhauser - Senior Scientist, University of Zurich, Zurich, Switzerland )

For HSCT in Ph-positive ALL

Prof Oliver Ottmann - Cardiff University, Cardiff, UK

For HSCT in Ph-positive ALL ( Prof Oliver Ottmann - Cardiff University, Cardiff, UK )

Bispecific T-cell engaging therapy for adult ALL

Prof Max Topp - University of Würzburg, Würzburg, Germany

Bispecific T-cell engaging therapy for adult ALL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )

Optimal use of TKIs for therapy of Ph-positive ALL

Dr Josep Ribera - Catalan Institute of Oncology, Badalona, Spain

Optimal use of TKIs for therapy of Ph-positive ALL ( Dr Josep Ribera - Catalan Institute of Oncology, Badalona, Spain )

Management of relapsed T-ALL in children

Prof Josef Vormoor - Newcastle University, Newcastle, UK

Management of relapsed T-ALL in children ( Prof Josef Vormoor - Newcastle University, Newcastle, UK )

Combining MRD quantitation and genetics in post-remission risk stratification

Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Combining MRD quantitation and genetics in post-remission risk stratification ( Dr John Moppett - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )

Transplanting adult ALL patients

Prof Sebastien Giebel - The Maria Skłodowska-Curie Institute of Oncology...

Transplanting adult ALL patients ( Prof Sebastien Giebel - The Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland )

Management of MLL-rearranged ALL

Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht...

Management of MLL-rearranged ALL ( Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht, Netherlands )

Against HSCT in Ph-positive ALL

Prof Robin Foa - Professor of Haematology and Head of Haematology, University...

Against HSCT in Ph-positive ALL ( Prof Robin Foa - Professor of Haematology and Head of Haematology, University of Rome, Rome, Italy )

CAR-T cells: challenges and opportunities

Dr Sara Ghorashian - University College London, London, UK

CAR-T cells: challenges and opportunities ( Dr Sara Ghorashian - University College London, London, UK )

Update on targeted therapies for Philadelphia-like ALL

Prof Stephen Hunger - Children’s Hospital of Philadelphia, Philadelphia, USA

Update on targeted therapies for Philadelphia-like ALL ( Prof Stephen Hunger - Children’s Hospital of Philadelphia, Philadelphia, USA )

More from ecancer